Strategic alliance Novalix is actively expanding its capabilities through recent partnerships and technology integrations, such as iBody Inc integration and switchSENSE technology, presenting opportunities to offer joint discovery platforms, antibody evaluation services, and enhanced biophysics support to biotech and pharma clients.

Biophysics expansion The addition of switchSENSE technology broadens Novalix’s biophysics capabilities, enabling sales conversations around advanced binding kinetics, real-time analysis, and high-throughput screening to differentiate from competitors.

Global partner network Novalix leverages a global business network through NovAliX SAS, which can be positioned as a gateway for multinational collaborations, enabling cross-border project opportunities and access to a broader customer base.

Preclinical focus With emphasis on improving outcomes at critical pre-clinical stages, the company can target biotech startups and mid-size pharma players seeking to de-risk early discovery programs through integrated platforms and expert scientific talent.

Growth signals Frequent leadership hires and regional business development roles indicate an active market expansion strategy, suggesting timing for outreach to identify potential co-development, licensing, or service partner opportunities in Europe and beyond.